(DIM) Sartorius Stedim Biotech - Ratings and Ratios
Bioreactors, Cell Culture Media, Reagents, Sensors, Analyzers, Chromatography
DIM EPS (Earnings per Share)
DIM Revenue
Description: DIM Sartorius Stedim Biotech
Sartorius Stedim Biotech SA is a leading provider of instruments and consumables for the biopharmaceutical industry, serving manufacturers of medications, vaccines, food, and chemicals, as well as research and development laboratories. The companys comprehensive product portfolio includes cell lines, bioreactors, reagents, and various solutions for separation, purification, and concentration processes.
Key Performance Indicators (KPIs) for Sartorius Stedim Biotech SA include a strong market presence in the healthcare equipment sector, with a market capitalization of approximately €19.5 billion. The companys revenue growth is driven by the increasing demand for biopharmaceuticals and the need for advanced manufacturing technologies. With a Return on Equity (RoE) of 5.19%, the company demonstrates a relatively stable profitability profile.
Further analysis of Sartorius Stedim Biotech SAs financials reveals a high Price-to-Earnings (P/E) ratio of 95.33, indicating a premium valuation relative to its earnings. However, the forward P/E ratio of 45.45 suggests a more moderate valuation relative to expected future earnings. This disparity may be attributed to the companys high growth prospects in the biopharmaceutical industry.
As a subsidiary of Sartorius AG, Sartorius Stedim Biotech SA benefits from its parent companys resources and expertise, enabling it to maintain a competitive edge in the market. With its headquarters in Aubagne, France, the company is well-positioned to serve the European and global biopharmaceutical markets.
Additional Sources for DIM Stock
DIM Stock Overview
| Market Cap in USD | 22,639m |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| GiC Sub-Industry | Health Care Equipment |
| IPO / Inception |
DIM Stock Ratings
| Growth Rating | -32.2 |
| Fundamental | -4.61 |
| Dividend Rating | 39.6 |
| Rel. Strength | 6.05 |
| Analysts | - |
| Fair Price Momentum | 144.76 EUR |
| Fair Price DCF | 84.80 EUR |
DIM Dividends
| Dividend Yield 12m | 0.38% |
| Yield on Cost 5y | 0.26% |
| Annual Growth 5y | 15.21% |
| Payout Consistency | 83.8% |
| Payout Ratio | 29.9% |
DIM Growth Ratios
| Growth Correlation 3m | -34.2% |
| Growth Correlation 12m | 44.6% |
| Growth Correlation 5y | -79.9% |
| CAGR 5y | -8.08% |
| CAGR/Max DD 5y | -0.11 |
| Sharpe Ratio 12m | 0.13 |
| Alpha | -12.32 |
| Beta | 0.532 |
| Volatility | 46.54% |
| Current Volume | 74.4k |
| Average Volume 20d | 69.7k |
| Stop Loss | 165.8 (-3.4%) |
As of August 02, 2025, the stock is trading at EUR 171.65 with a total of 74,413 shares traded.
Over the past week, the price has changed by -1.91%, over one month by -15.65%, over three months by -18.84% and over the past year by -6.43%.
Neither. Based on ValueRay´s Fundamental Analyses, Sartorius Stedim Biotech is currently (August 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -4.61 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of DIM is around 144.76 EUR . This means that DIM is currently overvalued and has a potential downside of -15.67%.
Sartorius Stedim Biotech has no consensus analysts rating.
According to our own proprietary Forecast Model, DIM Sartorius Stedim Biotech will be worth about 162.4 in August 2026. The stock is currently trading at 171.65. This means that the stock has a potential downside of -5.37%.
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 234.5 | 36.6% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 162.4 | -5.4% |